跳至主要内容
临床试验/IRCT20200415047080N1
IRCT20200415047080N1招募中3 期

A prospective randomized controlled trial to compare recombinant tissue-type plasminogen activator (rt-PA) and standard treatmentin in patients with ARDS induced by COVID-19

Tehran University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • A person with laboratory confirmation of COVID-19 infection
  • clinical and radiological confirmation of ARDS
  • The confirm case of covid-19 in patients with ARDS (PaO2/FiO2a = 300 or sat o2= 315 mmHg (with PEEP or CPAP = 5 cmH2O, or non-ventilated)

排除标准

  • Bleeding tendency
  • Coagulopathy (INR>1.5)
  • Thrombocytopenia (plt< 50000)
  • Previous hypersensitivity to Alteplase
  • Active internal bleeding
  • Severe uncontrolled hypertension
  • Severe renal disease (GFR<50 ml/min)
  • History of recent stroke
  • Hemoptysis at admission
  • Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years
  • Moderate to severe liver failure (Childs-Pugh Score > 12)
  • Major trauma in the prior 30 days
  • Moribund patient not expected to survive the next 24 hours.
  • No consent/inability to obtain consent

研究者

相似试验